Rajesh Kumar, HSBC Sr. health care analyst, joins CNBC's 'Money Movers' to discuss his reaction to a board shakeup at Novo Nordisk. Got a confidential news tip? We want to hear from you. Sign up for ...

Investing.com -- HSBC shifted its ratings across U.S. large-cap pharmaceuticals in a note on Wednesday, led by Rajesh Kumar, upgrading AbbVie to Buy while cutting Biogen to Reduce, as the bank ...

Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG Rajesh Kumar, HSBC's head of life sciences and healthcare research, discusses the key concerns facing anti-obesity drug manufacturers. Got a ...

GSK plc (NYSE:GSK) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. On December 10, HSBC analyst Rajesh Kumar raised the firm’s price target on GSK plc (NYSE:GSK) to 1,500 ...

Biogen (BIIB) traded lower on Wednesday after HSBC downgraded the company from Hold to Reduce, handing the Alzheimer’s drug developer its only sell-equivalent rating as part of an analysis that ...

InvestingPro data shows six analysts have recently revised their earnings estimates downward, suggesting broader concerns about near-term performance. Rajesh Kumar of HSBC highlighted three primary ...

HSBC analyst Rajesh Kumar downgraded Lilly stock to reduce this morning. Kumar believes GLP-1 demand, as measured in dollars, could be as little as half what other analysts forecast. Eli Lilly(NYSE: ...

On December 10, HSBC analyst Rajesh Kumar raised the firm’s price target on GSK plc (NYSE:GSK) to 1,500 GBp from 1,200 GBp and kept a Reduce rating on the shares. The move came as part of HSBC’s 2026 ...